EGFR and prostate cancer: In support of this possibility, a recent study using a dual EGFR/HER2 kinase inhibitor in prostate cancer cell lines showed that an HER2/ERBB3 signalling pathway protected the AR from degradation at low androgen concentrations through an AKT-independent pathway (Mellinghoff et al, 2004).